Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla., May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate,...